Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according to a group of abstracts presented at the Alzheimer’s Association International Conference.Intravenous lecanemab (Leqembi, Eisai) has yielded substantial reductions in amyloids and significantly slower clinical decline, Michael Irizarry, MD, MPH, senior vice president, clinical research, and deputy chief clinical officer at Eisai, and colleagues wrote.The FDA…
Source: Healio News
